Please assess the completion status of the following clinical trial:

Trial Title: Effects of Growth Hormone Releasing Hormone in HIV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women age 18-65~2. Previously diagnosed HIV infection~3. Stable antiviral regimen for at least 12 weeks prior to enrollment~4. WC\>95 cm and WHR\>0.94 for male, WC\>94 cm and WHR\>0.88 for female occurring in the context of treatment for HIV disease~5. Subjective evidence of at least one of the following recent changes, occurring during the treatment of HIV disease: increased abdominal girth, relative loss of fat in the extremities, or relative loss of fat in the face~6. For female subjects 40yo or older, negative mammogram within one year of baseline~Exclusion Criteria:~1. Use of anti-diabetic agents, Megace, testosterone or any steroid use within 6 months of the study. Stable use of testosterone (\> 6 mos) at dose equivalent to 200 mg IM q 2 weeks or \< 10g/day to skin will be permitted.~2. Use of GH or GHRH within the past 6 months~3. Change in lipid lowering or antihypertensive regimen within 3 months of screening~4. Fasting blood sugar \> 126 mg/dL, SGOT \> 2.5 times ULN, HgB \< 12.0 g/dL, creatinine \> 1.4 mg/dL, CD4 count \< 200~5. Severe chronic illness or active malignancy or history of pituitary malignancy or history of colon cancer~6. For men, history of prostate cancer or evidence of prostate malignancy by PSA \> 5 ng/mL~7. Prior history of hypopituitarism, head irradiation or any other condition known to affect the GH axis~8. For women, positive urine hCG~9. Oral contraceptives, depo provera or combined progesterone-estrogen injections, transdermal contraceptive patches, estrogen or progestin coated IUD's within 6 months of the study.~10. Routine MRI exclusion criteria such as the presence of a pacemaker or cerebral aneurysm clip.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Tesamorelin (Type: EXPERIMENTAL): Tesamorelin (growth hormone releasing hormone) 2mg daily given subcutaneously x 6 months during randomized phase, followed by 6 months of open-label tesamorelin at same dose
- Placebo (inactive injection) (Type: PLACEBO_COMPARATOR): Placebo 2mg daily given subcutaneously for the first 6 months of the study, followed by 6 months of tesamorelin (growth hormone releasing hormone) 2mg daily during an open label phase

Based on this trial design, predict the completion outcome and termination type (if applicable).